E
GOSS icon

Ergoteles’s Gossamer Bio GOSS Stock Holding History

Ergoteles’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,600
Closed -$25.9K – 375
2023
Q2 		$25.9K Sell
21,600
-1,710,324
-99% -$2.13M ﹤0.01% 978
2023
Q1 		$2.18M Buy
+1,731,924
New +$3.32M 0.09% 249
2022
Q1 		– Sell
-40,316
Closed -$456K – 1378
2021
Q4 		$456K Sell
40,316
-2,017
-5% -$24K 0.02% 679
2021
Q3 		$532K Buy
+42,333
New +$390K 0.02% 553

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ergoteles's GOSS Position: Q3 2023 in Review

Ergoteles sold out of Gossamer Bio (GOSS) in Q3 2023, closing a stake of 21,600 shares — an estimated $25.9K sold.

Ergoteles first reported a position in GOSS in Q3 2021 and held it in 4 quarters. The position peaked at $2.18M in Q1 2023. 95 funds tracked by Wall St. Rank hold GOSS as of Q3 2023.

  • Ergoteles reported no remaining Gossamer Bio position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 21,600 Gossamer Bio shares in Q3 2023, an estimated $25.9K.
  • Ergoteles first reported a position in Gossamer Bio in Q3 2021 and held it in 4 quarters.
  • Ergoteles's Gossamer Bio position peaked at $2.18M in Q1 2023.
  • 95 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.